Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2023
Reporting Period: Quarter ended March 31, 2023
Business Context: The filing serves as a notification of the company's financial results for the first quarter of 2023. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the announcement of financial results but does not contain the specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached Exhibit 99.1 (Press Release), which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms that results for the quarter ended March 31, 2023, were announced.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the information is furnished to comply with Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 8, 2023) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" referenced in Item 2.02.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the full press release.
- Confirm the company's cash runway and burn rate as detailed in the full financial disclosure.